MedTrace Logo

Combination Facial Aesthetic Treatment in Millennials

NCT04755595 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-01-14

Study results available
· View outcomes & findings →

Summary

With 63% of consumers willing to consider investing in facial aesthetics and 73% of consumers worldwide expecting to invest in aesthetic treatments in the upcoming year, it is imperative to explore patient satisfaction and psychosocial impact of a multimodal aesthetic treatment in a millennial cohort. The investigators hypothesize that a combination approach to facial aesthetic treatment in a millennial cohort will result in increased patient-reported satisfaction in multiple areas, including perception of aging concerns and quality of life.

Conditions

  • Dermatological Non-Disease

Interventions

DRUG

Botox Cosmetic Injectable Product

Acetylcholine release inhibitor and a neuromuscular blocking agent

DEVICE

Juvéderm Voluma XC

Gel implants consisting of cross-linked hyaluronic acid

DEVICE

Juvéderm Volbella XC

Gel implants consisting of cross-linked hyaluronic acid

Sponsors & Collaborators

  • Allergan Sales, LLC

    collaborator INDUSTRY

  • State University of New York - Downstate Medical Center

    lead OTHER

Principal Investigators

  • Jared Jagdeo, MD, MS · SUNY Downstate Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
24 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-09
Primary Completion
2021-05-19
Completion
2021-05-19
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04755595 on ClinicalTrials.gov